NCT07337174Not yet recruitingPhase 1
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
A Randomized, Open-label, Single Dose, Two-way, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 22 Dec 2025
- Start date
- 25 Jan 2026
- Primary completion date
- 24 Mar 2026
- Lead sponsor
- Huons Co., Ltd.
- Diseases
- Obesity
- NCT number
- NCT07337174
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 40
- From 25 Jan 2026 to the primary completion date, 24 Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders.
Other
- For females: Pregnant women (positive urine hCG) or nursing mothers.
Who the study is looking for
- Healthy adult volunteers aged 19 to 65 years, inclusive, at screening.
- Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period.
Age in the registry: 19 years to 65 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.